Home » Molecule

Molecule type

 

Accelera has proven experience with IND-enabling studies and with getting our clients’ investigational new drugs to market. With a unique range of services and best-in-class expertise, we help clients successfully initiate and complete their IND-enabling program on time and within budget. And, as a premium tier CRO, we can leverage this same experience to design suitable studies or programs for submission to regulatory authorities around the world.

 Small Molecules

We apply our knowledge gained from years of IND research and innovative technologies to help you successfully initiate and complete your IND-enabling program.

 Biologicals

Given the specialized nature of biologic development, you’ll benefit from the broadest set of capabilities across the industry. With full-service capabilities, Accelera provides you access to end-to-end preclinical solutions.

 Biosimilars

Combining years of experience in the development of biologic products with a deep knowledge of regulatory requirements, we can support our clients’ biosimilar programs with in vivo preclinical studies and preclinical and clinical sample analysis.

 ATMPs

Cell and gene therapies are classified as an advanced therapy medicinal products (ATMPs), these are subject to specific regulations and requires sophisticated testing technologies to bring to market. From regulatory expertise to a comprehensive portfolio of preclinical services, you’ll find everything you need to make your cell and gene therapies a reality at Accelera.